BackgroundCheck.run
Search For

Qi Chao, 66San Diego, CA

Known as:
Chao C Qi Chao Cenchen Qi Chao Q Chao Chao S Qi Chuck Q Qi Chaq Qi Chao Qu Teresa Donaghy

Qi Chao Phones & Addresses

San Diego, CA   

Lake Forest, IL   

Elmsford, NY   

Chappaqua, NY   

Buffalo Grove, IL   

Westchester, NY   

Ossining, NY   

Tarrytown, NY   

Social networks

Qi Chao

Linkedin

Work

Company: Shanghai chempartner ltd 2009 Position: Research fellow ii

Education

Degree: PhD School / High School: University of Tennessee-Knoxville 1990 to 1994 Specialities: Organic Chemistry

Skills

Drug Discovery • Dmpk • High Throughput Screening • Chemistry • Toxicology • Biotechnology • Medicinal Chemistry • Lifesciences • Biochemistry • Organic Synthesis • Lc Ms

Industries

Biotechnology
Get Report
Control this profile

Mentions for Qi Chao

Resumes & CV records

Resumes

Qi Chao Photo 16

Senior Scientist Ii

Location:
San Diego, CA
Industry:
Biotechnology
Work:
Shanghai ChemPartner Ltd since 2009
Research Fellow II Ambit Biosciences since Sep 2005
Sr. Scinetist III Salmedix, Inc. Jun 2001 - Sep 2005
Head of Chemistry Celgene Jan 1998 - Jun 2001
Scientist II University of California, San Diego Oct 1996 - Jan 1998
Post-Doctor University of Iowa Jun 1994 - Sep 1996
Post-Doctor
Education:
University of Tennessee-Knoxville 1990 - 1994
PhD, Organic Chemistry Fudan University 1984 - 1987
MS, Medicinal Chemistry
Skills:
Drug Discovery, Dmpk, High Throughput Screening, Chemistry, Toxicology, Biotechnology, Medicinal Chemistry, Lifesciences, Biochemistry, Organic Synthesis, Lc Ms

Publications & IP owners

Us Patents

Compounds And Methods For Modulation Of Estrogen Receptors

US Patent:
6593322, Jul 15, 2003
Filed:
Sep 21, 2000
Appl. No.:
09/668893
Inventors:
Shripad S. Bhagwat - San Diego CA
Bernd M. Stein - San Diego CA
Qi Chao - San Diego CA
Anthony R. Gangloff - Daly City CA
Jeffrey A. McKie - San Diego CA
Kenneth D. Rice - Mill Valley CA
Assignee:
Signal Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07D21718
US Classification:
51421301, 546144, 546140, 540539, 540597, 514307, 51421704, 5142352, 5142282, 514308, 51425305, 544128, 544 62, 544363
Abstract:
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER- over ER-. Methods are disclosed for modulating ER- in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Compounds And Methods For Modulation Of Estrogen Receptors

US Patent:
6686351, Feb 3, 2004
Filed:
Feb 27, 2002
Appl. No.:
10/085999
Inventors:
Shripad S. Bhagwat - San Diego CA
Qi Chao - San Diego CA
Assignee:
Signal Pharmaceuticals, Inc. - San Diego CA
International Classification:
C07D21718
US Classification:
51421301, 546144, 546140, 540593, 540597, 514307, 51421704, 5142352, 5142282, 514308, 51425305, 544128, 544 62, 544363
Abstract:
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective modulators for ER- over ER-. Methods are disclosed for modulating ER- in cell and/or tissues expressing the same, including cells and/or tissue that preferentially express ER-. More generally, methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natural hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Indazole Derivatives As Jnk Inhibitors And Compositions And Methods Related Thereto

US Patent:
6897231, May 24, 2005
Filed:
Jul 23, 2001
Appl. No.:
09/910950
Inventors:
Shripad S. Bhagwat - San Diego CA, US
Yoshitaka Satoh - San Diego CA, US
Steven T. Sakata - San Diego CA, US
Chris A. Buhr - Redwood City CA, US
Ronald Albers - La Jolla CA, US
John Sapienza - Chula Vista CA, US
Veronique Plantevin - San Diego CA, US
Qi Chao - San Diego CA, US
Kiran Sahasrabudhe - San Diego CA, US
Rachel Ferri - San Diego CA, US
Assignee:
Signal Pharmaceuticals, Inc. - San Diego CA
International Classification:
A61K031/416
C07D231/56
US Classification:
514403, 5483625, 5483611, 5483051, 5483117, 5482664
Abstract:
Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R, Rand A are as defined herein. Such compounds have utility in the treatment of a wide range of conditions that are responsive to JNK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compositions containing one or more compounds of the above compounds.

Indazole Compounds And Compositions Thereof As Jnk Inhibitors And For The Treatment Of Diseases Associated Therewith

US Patent:
7208513, Apr 24, 2007
Filed:
Nov 30, 2004
Appl. No.:
11/000462
Inventors:
Shripad S. Bhagwat - San Diego CA, US
Yoshitaka Satoh - San Diego CA, US
Steven T. Sakata - San Diego CA, US
Chris A. Buhr - Redwood City CA, US
Ronald Albers - La Jolla CA, US
John Sapienza - Chula Vista CA, US
Veronique Plantevin - San Diego CA, US
Qi Chao - San Diego CA, US
Kiran Sahasrabudhe - San Diego CA, US
Rachel Ferri - San Diego CA, US
Assignee:
Signal Pharmaceuticals, LLC - San Diego CA
International Classification:
A61K 31/416
C07D 231/56
US Classification:
514403, 5483611
Abstract:
Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure:.

Indazole Compounds And Compositions Thereof As Jnk Inhibitors And For The Treatment Of Diseases Associated Therewith

US Patent:
7211594, May 1, 2007
Filed:
Apr 16, 2003
Appl. No.:
10/414839
Inventors:
Shripad S. Bhagwat - San Diego CA, US
Yoshitaka Satoh - San Diego CA, US
Steven T. Sakata - San Diego CA, US
Chris A. Buhr - Redwood City CA, US
Ronald Albers - La Jolla CA, US
John Sapienza - Chula Vista CA, US
Veronique Plantevin - San Diego CA, US
Qi Chao - San Diego CA, US
Kiran Sahasrabudhe - San Diego CA, US
Rachel Ferri - San Diego CA, US
Assignee:
Signal Pharmaceuticals, LLC - San Diego CA
International Classification:
A61K 31/416
C07D 231/56
US Classification:
514381, 514403, 548250, 5483611
Abstract:
This invention is generally directed to Indazole Derivatives having the following structure:.

Methods Of Using Indazole Derivatives As Jnk Inhibitors

US Patent:
7220771, May 22, 2007
Filed:
Sep 26, 2003
Appl. No.:
10/673121
Inventors:
Shripad S. Bhagwat - San Diego CA, US
Yoshitaka Satoh - San Diego CA, US
Steven T. Sakata - San Diego CA, US
Chris A. Buhr - Redwood City CA, US
Ronald Albers - La Jolla CA, US
John Sapienza - Chula Vista CA, US
Veronique Plantevin - San Diego CA, US
Qi Chao - San Diego CA, US
Kiran Sahasrabudhe - San Diego CA, US
Rachel Ferri - San Diego CA, US
Assignee:
Signal Pharmaceuticals, LLC - San Diego CA
International Classification:
A61K 31/416
A61K 31/41
US Classification:
514403, 514381, 514383
Abstract:
Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure:.

Compounds And Methods For Modulation Of Estrogen Receptors

US Patent:
7279489, Oct 9, 2007
Filed:
May 7, 2003
Appl. No.:
10/434341
Inventors:
Shripad S. Bhagwat - San Diego CA, US
Bernd M. Stein - San Diego CA, US
Qi Chao - San Diego CA, US
Anthony R. Gangloff - Daly City CA, US
Jeffrey A. McKie - San Diego CA, US
Kenneth D. Rice - Mill Valley CA, US
Assignee:
Signal Pharmaceuticals, LLC - San Diego CA
International Classification:
A61P 35/00
A61K 31/47
C07D 217/00
US Classification:
514307, 546144
Abstract:
Compounds that modulate the estrogen receptor (ER) are disclosed, as well as pharmaceutical compositions containing the same. In a specific embodiment, the compounds are selective for ER-β over ER-α. Methods are disclosed for modulating ER-β in cell and/or tissues expressing the same, including cells and/or tissue that preferentially ER-β. Methods for treating estrogen-related conditions are also disclosed, including conditions such as is breast cancer, testicular cancer, osteoporosis, endometriosis, cardiovascular disease, hypercholesterolemia, prostatic hypertrophy, prostatic carcinomas, obesity, hot flashes, skin effects, mood swings, memory loss, urinary incontinence, hairloss, cataracts, natureal hormonal imbalances, and adverse reproductive effects associated with exposure to environmental chemicals.

Tetrahydropyrano-Indole Derivatives

US Patent:
7314886, Jan 1, 2008
Filed:
Oct 1, 2004
Appl. No.:
10/957039
Inventors:
Qi Chao - San Diego CA, US
Gary T. Elliott - San Diego CA, US
Lorenzo Leoni - Lodrino, CH
Mimi K. Phillips - San Diego CA, US
Assignee:
Cephalon, Inc. - Frazer PA
International Classification:
A61K 31/407
C07D 491/052
US Classification:
514411, 548432
Abstract:
Provided herein are indole derivatives, pharmaceutical compositions containing them, methods for their use, and methods for preparing these compounds.

Possible Relatives

Cynthia Chao  David Chao  Debra M Chao  Danny Chao  Dennis L Chao  Diana V Chao  Dorothy T Chao  Qi Lee  Qi Li  Qi D Lin 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.